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Ebola virus (EBOV) is an enveloped, ssRNA virus from the family Filoviridae capable
of causing severe hemorrhagic fever with up to 80–90% mortality rates. The most
recent outbreak of EBOV in West Africa starting in 2014 resulted in over 11,300 deaths;
however, long-lasting persistence and recurrence in survivors has been documented,
potentially leading to further transmission of the virus. We have previously shown that
exosomes from cells infected with HIV-1, HTLV-1 and Rift Valley Fever virus are able
to transfer viral proteins and non-coding RNAs to naïve recipient cells, resulting in an
altered cellular activity. In the current manuscript, we examined the effect of Ebola
structural proteins VP40, GP, NP and VLPs on recipient immune cells, as well as
the effect of exosomes containing these proteins on naïve immune cells. We found
that VP40-transfected cells packaged VP40 into exosomes, and that these exosomes
were capable of inducing apoptosis in recipient immune cells. Additionally, we show
that presence of VP40 within parental cells or in exosomes delivered to naïve cells
could result in the regulation of RNAi machinery including Dicer, Drosha, and Ago
1, which may play a role in the induction of cell death in recipient immune cells.
Exosome biogenesis was regulated by VP40 in transfected cells by increasing levels
of ESCRT-II proteins EAP20 and EAP45, and exosomal marker proteins CD63 and Alix.
VP40 was phosphorylated by Cdk2/Cyclin complexes at Serine 233 which could be
reversed with r-Roscovitine treatment. The level of VP40-containing exosomes could
also be regulated by treated cells with FDA-approved Oxytetracycline. Additionally,
we utilized novel nanoparticles to safely capture VP40 and other viral proteins from
Ebola VLPs spiked into human samples using SDS/reducing agents, thus minimizing
the need for BSL-4 conditions for most downstream assays. Collectively, our data
indicates that VP40 packaged into exosomes may be responsible for the deregulation
and eventual destruction of the T-cell and myeloid arms of the immune system
Frontiers in Microbiology | www.frontiersin.org 1 November 2016 | Volume 7 | Article 1765
fmicb-07-01765 April 13, 2018 Time: 15:23 # 2
Pleet et al. Ebola Exosomes Kill Immune Cells
(bystander lymphocyte apoptosis), allowing the virus to replicate to high titers in the
immunocompromised host. Moreover, our results suggest that the use of drugs such
as Oxytetracycline to modulate the levels of exosomes exiting EBOV-infected cells may
be able to prevent the devastation of the adaptive immune system and allow for an
improved rate of survival.
Keywords: Ebola virus, EBOV, VP40, VLP, exosomes, ESCRT, microRNA, apoptosis
INTRODUCTION
Ebola virus (EBOV), a member of the family Filoviridae, is an
enveloped, non-segmented, single-stranded, negative sense RNA
virus first recognized in 1976 (Ebola Virus Infection, 1977; Foster,
1999). EBOV can cause severe hemorrhagic fever in humans and
non-human primates, resulting in high rates of morbidity and
mortality (Elshabrawy et al., 2015; Singh et al., 2015). The largest
and most recent outbreak of EBOV occurred in West Africa
starting in August of 2014, resulting in over 28,600 cases and
more than 11,300 deaths as of April 2016 according to the CDC
(2016). The cellular tropism of EBOV is fairly broad, targeting
mainly monocytes, macrophages, Kupffer cells and dendritic
cells early in infection, helping to maintain the replication and
spread of the virus (Martines et al., 2015; Messaoudi et al., 2015;
Singh et al., 2015). While EBOV infection results in a massive
systemic cytokine storm correlating with the poor prognosis of
patients, the virus also utilizes several immune evasion strategies
once inside host cells, including downregulation of cytokines
and IFNα/β, dsRNA masking, inhibition of T cell activation by
dendritic cells, and blocking of innate immune system signaling
cascades (Messaoudi and Basler, 2015; Messaoudi et al., 2015;
Rougeron et al., 2015; Singh et al., 2015).
While EBOV disease has not yet been recognized to exhibit
latency, there have been several recent cases of a recurrence
of infection in survivors of acute EBOV infection. Despite
clearance of virus from the blood, EBOV is able to persist in
immunologically protected sites in the body, including ocular
fluid, semen, and vaginal fluids, as well as in sweat, urine, and
breast milk (Deen et al., 2015; Varkey et al., 2015; Chancellor
et al., 2016; Harries et al., 2016; MacIntyre and Chughtai, 2016).
A recent study of survivors in Sierra Leone showed that EBOV
may persist for much longer than previously recognized, with
over 1 in 4 male EBOV survivors containing virus in their semen
for up to 7–9 months post disease onset (Deen et al., 2015).
Furthermore, this persistence may lead to transmission of the
virus. One case involving a 44-year-old woman in Liberia in 2015
involved a potential transmission link from a 46-year-old man
that had recovered from EBOV in late September of 2014. Testing
of the semen by RT-PCR 199 days following the male patient’s
recovery showed positive results for EBOV of the same genetic
strain as the female patient (Christie et al., 2015; MacIntyre and
Chughtai, 2016). The mechanism underlying viral persistence
and possible recurrence in survivors is not well understood, but
should be more fully investigated.
Ebola virus is composed of seven genes that encode eight
proteins including: the nucleoprotein (NP); viral proteins VP24,
VP30, VP35, and VP40; viral RNA-dependent RNA polymerase
(L) and two possible forms of glycoprotein (GP). The EBOV
GP protein is the sole protein expressed on the surface of
the virus, and is essential in the attachment of EBOV to host
cells (Lee and Saphire, 2009; Nyakatura et al., 2015). The
mechanism of entry of EBOV into host cells is mainly via
GP-dependent macropinocytosis followed by trafficking through
endosomal vesicles (Nanbo et al., 2010; Saeed et al., 2010;
Messaoudi et al., 2015), although the factors that direct the
movement of endosomal virus vesicles are not fully understood
(Sakurai et al., 2015). NP is an essential component of the
nucleocapsid, and coats the viral genome prior to packaging into
new infectious virions and release from the cell (Falasca et al.,
2015; Messaoudi et al., 2015; Rougeron et al., 2015).
VP40 is the EBOV matrix protein and plays an essential
role in driving the assembly and budding of new viral particles
(Panchal et al., 2003; Silva et al., 2012; Soni and Stahelin, 2014). It
forms a coating with the inner leaflet of the lipid bilayer, where
it then oligomerizes in lipid rafts and recruits other host cell
factors such as TSG101, Alix, and other machinery associated
with the Endosomal Sorting Complex Required for Transport
(ESCRT) complexes to aid in the budding and release of new
virions (Martin-Serrano et al., 2001; Licata et al., 2003; Panchal
et al., 2003; Silvestri et al., 2007; Han et al., 2015). VP40 alone
is capable of spontaneously releasing virus-like particles (VLPs)
from infected cells, which are similar in size and structure to
infectious virions (Timmins et al., 2001; Bavari et al., 2002;
Panchal et al., 2003). This budding phenomena is enhanced
by the addition of GP and/or NP in association with VP40
(Bavari et al., 2002; Noda et al., 2002; Licata et al., 2004). Due
to their morphological similarity to Ebola virions, VLPs have
been utilized as a surrogate research model to study filoviruses
outside of BSL-4 conditions (Kallstrom et al., 2005). Additionally,
EBOV VP40 may potentially act as a suppressor of the RNA
interference (RNAi) pathway, a widely conserved gene regulatory
mechanism responsible for providing an innate response to
viral infection through the production of microRNAs (miRNA),
thereby inhibiting innate antiviral responses of the host (Fire
et al., 1998; Novina and Sharp, 2004; Fabozzi et al., 2011).
In recent years, much interest has been focused on
mechanisms of intracellular delivery of nucleic acids, miRNAs,
and proteins between cells, particularly in the context of
infections. Nanovesicles called exosomes are small membrane-
bound vesicles that originate from late endosomes, which
act as intercellular messengers and transport biological
macromolecules from one cell to another (Théry et al., 2002;
Février and Raposo, 2004; Fleming et al., 2014). Cellular proteins,
as well as mRNA and miRNA, can be carried by exosomes to
induce a change in recipient cells (Lotvall and Valadi, 2007; Skog
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et al., 2008). Additionally, exosomes from virally infected cells
such as Epstein-Barr, Kaposi sarcoma-associated herpesvirus,
HIV-1, and Rift Valley Fever Virus have been shown to transfer
viral non-coding to neighboring uninfected cells, resulting in
altered cellular activity (Pegtel et al., 2010; Barth et al., 2011;
Pegtel et al., 2011; Ahsan et al., 2016; Sampey et al., 2016). If
there is indeed latency in Ebola infection, it is possible that the
virus could potentially utilize exosomes to transport viral nucleic
acid and proteins to other neighboring cells, explaining in part
the observed pathogenesis.
In this study, we examined the effect of Ebola structural
proteins VP40, GP, NP and VLPs on recipient immune cells, as
well as the effect of transfected cell exosomes on naïve immune
cells. We found that VP40 is indeed packaged into exosomes
and that these exosomes are capable of inducing programmed
cell death in recipient immune cells. Additionally, we show that
presence of VP40 within cells or contained in exosomes can
result in an altered expression of RNAi components in host cells.
Presence of VP40 in cells induced an upregulation of extracellular
CD63 and Alix, as well as ESCRT-II proteins EAP20 and EAP45,
indicating that VP40 may be capable of increasing exosomal
biogenesis. We also found that VP40 is phosphorylated by
Cdk2/Cyclin E and Cdk2/Cyclin A complexes at the G1/S border
and can be reversed with Cdk2 inhibitors. Finally, we show
that specific nanoparticles are able to capture and detect Ebola
proteins present in human samples under BSL-2 conditions,
potentially representing a novel diagnostic tool that could easily
be used in the field. Overall, our data indicates that the VP40
packaged into exosomes may be responsible for the bystander
lymphocyte apoptosis and dysregulation of the immune system
observed during pathogenesis, allowing for high levels of viral
replication in immunocompromised infected individuals.
MATERIALS AND METHODS
Cell Culture and Reagents
CEM, Jurkat and U937 cells were obtained from ATCC
(Manassas, VA, United States) and maintained in RPMI-1640
media containing 10% heat-inactivated fetal bovine serum
(FBS), 1% L-glutamine, and 1% streptomycin/penicillin (Quality
Biological, Gaithersburg, MD, United States). Monocytic U937
cells were induced to differentiate into monocyte-derived
macrophages (MDM) with 50 nM of phorbol-12-myristate-
13-acetate (PMA; Sigma–Aldrich) for 5 days. The primary
monocytes were isolated from peripheral blood mononuclear
cells (PBMCs; purchased from Precision Biosciences) and
maintained in RPMI-1640 media as described above. Primary
monocytes isolated from PBMCs were induced to differentiate
into MDMs with 10 nM of phorbol-12-myristate-13-acetate
(PMA) for 2 days. HEK-293T cells were maintained in
Dulbecco’s modified minimum essential medium (DMEM)
media containing 10% heat-inactivated FBS, 1% L-glutamine, and
1% streptomycin/penicillin (Quality Biological, Gaithersburg,
MD, United States). All cells were incubated at 37◦C in the
presence of 5% CO2.
For antibiotic selection of transfected 293T cells, Hygromycin
B (Invitrogen), Zeocin (Life Technologies), or Geneticin (Life
Technologies) were added to the culture next day. Hydroxyurea
(Sigma–Aldrich) and r-Roscovitine (Cell Signaling Technology)
were used for the treatment of transfected cell cultures for
in vivo labeling followed by kinase assay. Other Cdk2 inhibitors
used for kinase assays (Alsterpaullone, Indirubin-3′-monoxime,
and Purvalanol A) were purchased from Sigma–Aldrich.
Treatment of transfected 293T cells with Oxytetracycline (Selleck
Chemicals), Esomeprazole (Selleck Chemicals), and Cambinol
(Sigma–Aldrich) for analysis of levels of exosomal markers
took place the day following transfection. All experiments
involving biohazards were carried out under the IBC-approved
institutional biosafety guidelines and were performed at BSL-2
level.
Plasmids, Transfections, and Generation
of Resistant Clones
Ebola structural proteins were expressed from plasmids
(Invitrogen) with CMV promoters and specific antibiotic
selection markers: GP (pcDNA3.1/Zeo), NP [pcDNA3.1
(±)], VP40 (pcDNA3.1/Hygro). Twenty microgram of
Escherichia coli-purified DNA was transfected into 293T
cells using either Attractene reagent (Qiagen, Chatsworth, CA,
United States) according to the manufacturer’s instructions, or by
electroporation as previously described (Kashanchi et al., 1992).
Transfected cells were treated next day with either 100 µg/mL
Zeocin (CMV-GP), 500 µg/mL Geneticin (CMV-NP), or
200 µg/mL Hygromycin B (CMV-VP40) for plasmid selection.
To generate resistant clones, transfected cells were cultured for
>2 weeks, followed by isolation of surviving colonies (<1% of
cells) and multiple passages under specific antibiotic selection.
A total of 13 resistant clones were generated, but only 2 survived
after >10 passages: one GP-clone (data not shown) and one
VP40-clone (EVTR2C). All resistant clones were kept under
constant antibiotic selection.
Capture of Exosomes, Ebola VLPs, and
Proteins with Nanotrap Particles
The nanotraps utilized here are multifunctional hydrogel
particles 700–800 nm in diameter composed of high affinity
aromatic baits containing a core surrounded by a sieving shell
with pores that will selectively allow the passage of smaller
molecules. Polymerization reactions with reactants N-isopropyl
acrylamide (NIPAm), N,N-Methylenebisacrylamide (Bis) and
either allylamine (AA), acrylic acid (AAc) or methacrylate (MA)
are required for the synthesis of the particle’s shell. Vinyl sulfonic
acid (VSA) monomers may also be incorporated into the shell
for greater exclusion of high molecular weight and highly
abundant analytes. Specific high affinity charge-based baits are
covalently attached to the core matrix and bind target molecules
through hydrophobic and electrostatic interactions, preventing
degradation while sequestering the targets. NT80 beads contain
Reactive Red 120 core bait while NT82 beads have Cibacron
Blue F3GA. Both bead types have a NIPAm-Bis-AA matrix with
a shell lacking VSA (Jaworski et al., 2014b). The characteristics
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of the newer nanotrap particles utilized in this manuscript are
outlined in Figure 3B. For the capture and isolation of exosomes
from transfected cell culture supernatants, a 20 µL slurry (30%)
of 1:1 NT80 and NT82 nanotrap particles (Ceres Nanosciences)
was incubated with 500 µL of cell-free supernatant. For capture
of exosomes from resistant clone cell culture supernatants, a
25 µL slurry (30%) of NT80/82 beads (1:1) was incubated with
1 mL of cell-free, filtered (0.22 micron) supernatant. Samples
were bound at 4◦C for 72 h. NT pellets were isolated and
washed with 500 µL of sterile 1x PBS without calcium and
magnesium, followed by resuspension in 20µL of Laemmli buffer
for SDS/PAGE. For the capture and isolation of VP40, 69 ng
of E. coli-purified VP40 was spiked into 100 µL of PBS and
incubated with 20 µL of slurry (30%) of nine different NTs (210,
212, 213, 217, 219, 222, 223, 224, and 229) overnight at 4◦C. Beads
were washed with sterile 1x PBS without calcium and magnesium
and resuspended in 20 µL Laemmli buffer for SDS/PAGE.
For the capture and isolation of VLP in the presence of SDS,
20 µL of 30% slurry of the 9 NTs listed above was incubated
with 1 µg of purified VLP in 80 µL SDS buffer [1:4; 20 µL
Laemmli buffer and 60 µL Radioimmunoprecipitation assay
(RIPA) buffer] overnight at 4◦C. NT pellets were washed once
with 500 µL of TNE50 + 0.1% NP40, followed by resuspension
in Laemmli buffer for SDS/PAGE. For capture and isolation of
VLP-derived VP40 in human samples, 100 µL of healthy human
saliva (BioreclamationIVT, Baltimore, MD, United States), urine
(obtained from a healthy male lab worker), and serum (#AY217;
NCI bank transferred to FK) from healthy anonymous donors
were diluted 1:3 in sterile 1x PBS without calcium and magnesium
and spiked with 2.5 µg of purified Ebola VLP. One hundred
and fifty microliters each of RIPA and Laemmli buffer (total
300 µL of 1:1 SDS buffer) was added to each sample, followed
by addition of 60 µL of a 30% slurry of NT219. Samples
were incubated overnight at 4◦C, washed once with 500 µL of
TNE50 + 0.1% NP40, and resuspended in 20 µL of Laemmli
buffer for SDS/PAGE.
Cell Treatment and Viability Assay
Cells were seeded into 96 well plates at 50,000 cells per well
in fresh media followed by treatment. For treatment of CEM,
Jurkat, and U937 cells with VLP or VP40, 0.1 or 0.5 µg of
VLP or E. coli-purified VP40 (generously provided by IBT
Bioservices) was placed into 100 µL of cells suspended in fresh
media. For treatments with cell culture supernatants, transfected
cells or resistant clones were cultured for 5 days to maximize
the concentration of exosomes within the media as previously
described (Narayanan et al., 2013). Media was then harvested
from the cells, centrifuged for 10 min at 14,000 rpm to remove
cells and cellular debris, and either filtered (0.22 micron) or
left unfiltered. Seeded cells in fresh media (50 µL total) were
then treated with 50 µL of supernatant. All treatments of
CEM, Jurkat, and U937 cells were allowed to incubate for
5 days followed by measurement of cell viability using CellTiter-
Glo Cell Luminescence Viability kit (Promega, Madison, WI,
United States) as per manufacturer’s instructions. Briefly, 100 µL
CellTiter-Glo reagent was added to the wells (1:1 reagent:cell
suspension) and incubated at room temperature for 10 min
followed by detection of luminescence using the GLOMAX
multidetection system (Promega). Primary macrophages were
assayed for cell viability 2 days following treatment.
Preparation of Whole Cell Extracts,
Western Blot Analysis, and Densitometry
Cell pellets were harvested, washed twice with 1x PBS without
calcium and magnesium, and resuspended in lysis buffer [50 mM
Tris-HCl (pH 7.5), 120 mM NaCl, 5 mM EDTA, 0.5% Nonidet
P-40, 50 mM NaF, 0.2 mM Na3VO4, 1 mM DTT, and 1
complete protease inhibitor mixture table/50 mL (Roche Applied
Science, Mannheim, Germany)]. The suspension was incubated
on ice for 20 min with gentle vortexing every 5 min, followed
by centrifugation at 10,000 rpm at 4◦C for 10 min. Protein
concentration from the lysate supernatant was determined using
the Bradford protein assay (Bio-Rad).
Whole cell extracts (10 µg) were resuspended in 10 µL
Laemmli buffer, heated at 95◦C for 3 min, and loaded onto
a 4–20% Tris-glycine SDS gel. Nanotrap particle pellets were
resuspended in 15 µL Laemmli buffer, heated at 95◦C for 3 min
and vortexed three times until fully resuspended, and then loaded
onto a 4–20% Tris-glycine SDS gel. Gels were run at a maximum
160 V and transferred overnight onto PVDF membranes.
Membranes were blocked in 5% milk in 1x PBS containing 0.1%
Tween 20 for 1 h at 4◦C, then incubated overnight at 4◦C with
appropriate primary antibody: [α-Caspase 3, α-PARP-1, α-Alix,
α-CHMP6, α-TSG101, α-EAP20, α-EAP45, α-TRBP (Santa
Cruz Biotechnology); α-Dicer, α-Drosha, α-Ago1, α-Exportin
5, α-DGCR8, α-CD63, α-β-actin, (Abcam); α-VP40 and α-GP]
were generously provided by IBT Bioservices. Membranes were
then incubated with the appropriate HRP-conjugated secondary
antibody for 2 h at 4◦C and developed using SuperSignal
West Dura Extended Duration Substrate (Pierce, Rockford, IL,
United States). Luminescence was visualized on a Kodak 1D
image station (Carestream Health, Rochester, NY, United States).
Raw densitometry counts were obtained using ImageJ software.
Identification of Potential
Phosphorylation Sites in VP40 Protein
Mass spectra for VP40 was obtained for this manuscript as
previously described in our analysis of VP30 from EBOV virions
(Ilinykh et al., 2014). Proteomics data for VP40 had not been
previously published. The spectra were analyzed by SEQUEST
(Thermo) search engine. Protein phosphorylation sites were
detected with Proteome Discoverer 1.4 software and mapped to
the VP40 protein sequence.
Immunoprecipication, in vivo Labeling,
and Kinase Assays
Immunoprecipitation (IP) was performed by incubation
of 500 µg of CEM or transfected and treated 293T whole
cell extracts with 10 µg of appropriate primary antibody
(α-Cdk2, α-CycE, α-CycA, α-normal rabbit IgG; Santa Cruz
Biotechnology) and 100 µL TNE50 + 0.1% NP-40 for 48 h at
4◦C. CEM cells were utilized for these experiments as we have
previously shown that these cells contain active Cdk/Cyclin
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complexes that can easily be purified using specific antibodies
(Wang et al., 2001). The next day, complexes were precipitated
with 30 µL of a 30% slurry of A/G beads (Calbiochem) for 2 h
at 4◦C, washed twice with TNE50 + 0.1% NP-40 and twice
with kinase buffer. The reaction mixtures (20–30 µL) contained
the following final concentrations: 40 mM β-glycerophosphate
(pH 7.4), 7.5 mM MgCl2, 7.5mM EGTA, 5% glycerol, [γ-32P]
ATP (0.4 mM, 1 µCi), 50 mM NaF, 1 mM orthovanadate, and
0.1% (v/v) β-mercaptoethanol. Phosphorylation reactions were
performed with immunoprecipitated material and E. coli-purified
VP40 (0.5 µg) as a substrate in TTK kinase buffer containing
50 mM HEPES (pH 7.9), 10 mM MgCl2, 6 mM EGTA, and
2.5 mM dithiothreitol. Reactions were incubated at 37◦C for
1 h, stopped by the addition of 1 volume of Laemmli sample
buffer containing 5% β-mercaptoethanol, and run on 4–20%
SDS-polyacrylamide gel. Gels were subjected to autoradiography
and quantification using PhosphorImager software (Amersham
Biosciences). Kinase assay with peptides was accomplished by
adding 50 µg appropriate peptide [S3 (ADLTSPEKIQAI),
S3M (ADLTAPEKIQAI), T7 (GKKVTAKNGQPI), S8
(GKKVASKNGQPI), T2 (LVHKLTGKKV) (Biomatik USA,
LLC, Wilmington, DE, United States)] and 15 µL of appropriate
antibody (α-CycE, α-IgG) to the Protein A/G pellet suspended
in kinase buffer (120 µL). Next, [γ-32P] ATP was added
to the samples, incubated at 37◦C for 1 h, and samples
(10 µL) were dotted onto Whatman glass microfiber filters,
dried for 30 min, and subsequently submerged in TE buffer
with gentle agitation for 48 h. Samples were quantified
using a scintillation counter (QuantaSmartTM DPM assay
count).
For in vivo labeling, 293T cells (5 × 106) were electroporated
with 20 µg of VP40 plasmid, followed by addition of Hygromycin
B (200 µg/mL). Cells were grown up to 30–40% confluency
(4 days) at which time Hydroxyurea (G1/S blocker; 1 mM)
was added for one additional day. Media were removed and
1 mL of DMEM was added to cover the cells, with the
addition of 10 µL of [γ-32P] ATP (∼3000 mCi/mL) for 4 h.
Next, r-Roscovitine (1–10 µM) was also added to a few
of the samples. After labeling, cells were chased with cold
complete media (no radioactivity) for 2 h. Cells were removed
with a cell scraper and lysed in lysis buffer, followed by IP
with α-VP40 antibody overnight in TNE150 + 0.1% NP-40.
Protein A/G was added and bound beads were washed 2x with
TNE150 + 0.1% NP-40 and once with kinase buffer. Pellets
were then resuspended in Laemmli buffer and run on 4–20%
SDS-polyacrylamide gel. Gels were subjected to autoradiography
and quantification using PhosphorImager software (Amersham
Biosciences).
Isolation of Exosomes and AChE Assay
293T, transfected 293T, and EVTR2C cells were grown in DMEM
containing 10% heat-inactivated FBS, 1% L-glutamine, and 1%
streptomycin/penicillin (Quality Biological, Gaithersburg, MD,
United States). Exosome preparation was made from 100 mL
of cell culture supernatant (produced from fully confluent cells
grown for 5 days). Cells were pelleted by centrifugation at 300 g
for 10 min. An additional centrifugation at 2000 g for 10 min
was used to pellet dead cells. The resulting supernatant was
then filtered through a 0.22 micron filter and ultracentrifuged
at 10,000 g for 30 min. This resulting supernatant was then
pulled off and ultracentrifuged at 100,000 g for 70 min to
pellet the exosomes. These exosomes were then washed with
22.5 mL of sterile 1x PBS without calcium and magnesium
and ultracentrifuged again at 100,000 g for 70 min. The
supernatant was pulled off and the final pellet was resuspended
in 100 µL of PBS. All spins were performed at 4◦C. Protein
levels of the exosomes were determined with the Amplex R©
Acetylcholine/Acetylcholine Esterase Activity Assay Kit (Thermo
A12217) following the manufacturer’s instructions. Briefly, a 1x
running buffer negative control (20 mL of H2O and 5 mL of
5x reaction buffer) and two positive controls, one consisting of
acetylcholine esterase and one consisting of hydrogen peroxide,
were made and plated on a 96-well plate. Exosomes were treated
and fluorescence of acetylcholine esterase activity was measured
with a GLOMAX multidetection system (Promega) every 15 min
for 1 h to find optimal activity.
Statistical Analysis
Standard deviation was calculated in all quantitative experiments
done in triplicate. All p-values were calculated using two-tailed
Student’s t-tests (Microsoft Excel) and were considered to be
statistically significant when p < 0.05.
RESULTS
Treatment of Immune Cells with Ebola
VLP or VP40 Deregulates Cell Growth
It has been well documented that EBOV as well as Ebola
VLPs are capable of inducing significant cell death as well
as cytokine storm in vitro and in vivo (Wauquier et al.,
2010; Wahl-Jensen et al., 2011; Falasca et al., 2015; Messaoudi
and Basler, 2015), particularly in macrophages and dendritic
cells. Additionally, bystander lymphocyte apoptosis has been
observed in many experimental and clinical models of Ebola
infection (Geisbert et al., 2003; Wauquier et al., 2010). However,
direct cell regulation of lymphocytes has not been studied
by Ebola viral VLPs or structural proteins. We hypothesized
that one or more of EBOV proteins may cause deregulation
of cell growth on recipient immune cells. To this end, we
incubated increasing concentrations of VLP and VP40 with three
immune cell types, including two types of T-cells (early and
late developmentally deregulated cells represented by CEM and
Jurkat cells, respectively) and one monocyte cell line (U937), and
assayed for cell viability using CellTiter-Glo. Purified E. coli-made
VP40 was utilized, as the other two proteins GP and NP also
found in VLPs were insoluble using prokaryotic vectors (data
not shown). Only two concentrations of VLP and VP40 were
used for these experiments due to limited availability of reagents.
Results in Figure 1A show that VLPs (at varying concentrations)
were not apoptotic in lymphocytes, while monocytes showed a
slight decrease in cell viability at higher VLP concentrations. On
the other hand, when using E. coli-purified VP40, the two T-cell
lines showed a decrease in viability (Figure 1B). To verify the
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FIGURE 1 | Treatment of recipient cells with EBOV VLPs and free VP40. Mid log phase CEM, Jurkat (T-cells) and U937 (monocyte) cells (5 × 104) were treated
with either Ebola VLPs containing GP, NP, and VP40 (A) or E. coli-purified VP40 protein (B) in concentrations of 0.1 or 0.5 µg and incubated for 5 days, followed by
cell viability assay with CellTiter-Glo. (C) VLP and purified VP40 proteins (0.1 or 0.5 µg) were run on a 4–20% SDS/PAGE and analyzed by Western blot for levels of
VP40. Percentage of VP40 with 5 µg purified VLP positive control set to 100% was determined by densitometry and is shown in the bottom panel. (D) Two hundred
microliters of CEM, Jurkat, and U937 cells (5 × 105) was treated with 1 µg of Ebola VLP or E. coli-purified VP40 protein and incubated for 5 days. Cells were lysed,
run on a 4–20% SDS/PAGE, and analyzed by Western blot for the presence of apoptotic markers Pro-Caspase 3, cleaved and un-cleaved PARP-1, and Actin.
relative levels of VP40 in the purified VP40 versus that found in
the VLPs, assessment by Western blot showed a slightly higher
amount of VP40 (approximately 1.75-fold higher levels of VP40
compared to VLP, as determined by densitometry analysis) in
the E. coli-purified preparation than that in VLPs (Figure 1C).
Importantly, VP40 within VLPs is likely to be hidden under the
envelope, therefore only the unmasked VP40 decreased T-cell
viability shown in Figure 1B. We have recently shown that
analysis of apoptotic markers Caspase 3 and PARP-1 by Western
blot in the case of Rift Valley Fever virus infection indicated
cell death by apoptosis in Jurkat cells treated with exosomes
containing proteins from RVFV resistant clones (Ahsan et al.,
2016). Similarly, here T-cells and monocytes treated with VP40
showed increased pro-Caspase cleavage and accumulation of
cleaved PARP-1 (Figure 1D), confirming that cells treated with
free VP40 protein initiated programmed cell death. The levels
of Actin in the VP40-treated lanes (lanes 3, 6, and 9) decrease
as well, which is also indicative of cell death. Collectively, these
results indicate that free VP40 can induce apoptosis in immune
cells, especially in T-cells.
Treatment with Ebola Structural
Protein-Transfected Cell Supernatants
Deregulates Immune Cell Growth
Ebola-infected cells are capable of production and release or
accumulation of EBOV proteins in a cell type dependent manner
(Steele et al., 2001). As we have previously shown dysregulation
of immune cells by supernatants from HIV, HTLV, and Rift
Valley Fever virus infected cells (Narayanan et al., 2013; Jaworski
et al., 2014a; Ahsan et al., 2016; Sampey et al., 2016), we wished
to determine whether supernatants from cells transfected with
Ebola structural protein-containing plasmids would impact the
viability of neighboring uninfected cells. We transfected 293T
cells with VP40, GP, and NP plasmids followed by specific
antibiotic selection for each plasmid. The supernatants from
the transfected cells were isolated and used to treat uninfected
CEM, Jurkat, and U937 cells. Cell viability was assayed 5 days
following treatment using CellTiter-Glo. Statistical analyses were
performed comparing filtered supernatants from transfected cell
to filtered supernatants from control 293T cell treatments, and
likewise for the unfiltered groups. As shown in Figure 2A,
only CEM cells treated with supernatants from VP40-transfected
293T cells showed significant reduction in viability. However,
supernatants from NP- or GP-transfected cells had minimal effect
on CEM cell viability. Jurkat T-cells showed significant decreases
in viability following treatments with VP40 and NP transfection
supernatants in contrast to treatment with GP-transfected cell
supernatants (Figure 2B). Interestingly, CEM cells are derived
from the T lymphoblast whereas Jurkat cells originate from
the more differentiated peripheral blood T lymphocyte. As
such, the differential dysregulation seen between these two
cell types may be an indication of selective susceptibility of
T cells to Ebola structural proteins based on their stage of
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FIGURE 2 | Treatment of immune cells with filtered and unfiltered Ebola-transfected cell supernatants. 293T cells were transfected with either VP40, GP,
or NP plasmids with Attractene Transfection Reagent (Qiagen) as per the manufacturer’s instructions and incubated for 2 days. Transfection complexes were
removed and cells were treated with antibiotics for plasmid selection for 14 days. Transfection supernatants were either left unfiltered or passed through a 0.22
micron filter. Control 293T cells were not transfected nor treated with antibiotics (Hygromycin B, Zeocin, or Geneticin). Seventy-five microliters (0.45 mU AChE) of
both filtered and unfiltered supernatants were used to treat CEM (A), Jurkat (B) and U937 (C) cells, which were subsequently assayed for cell viability via
CellTiter-Glo after 4 days of incubation. Statistical significance was determined using 2-tailed student’s t-test, with filtered or unfiltered experimental values compared
to the Control values of like type. (D) U937 cells were treated with PMA (50 nM) for 5 days to stimulate differentiation into macrophages. On day 5 media was
replaced and differentiated U937 macrophages were treated with either E. coli-purified free VP40 protein, or supernatants from VP40-transfected 293T cells (filtered
and unfiltered). Untreated macrophages received no external supernatant treatment. Cells were incubated for an additional 5 days and cell viability was assayed with
CellTiter-Glo. (E) Primary monocytes from 3 healthy donors were treated with PMA (10 nM) for 2 days to stimulate differentiation into macrophages. Primary
macrophages were then treated with supernatants from either VP40-transfected 293T cells (filtered and unfiltered), or from VP40-resistant clone EVTR2C cells
(filtered). Control primary macrophages were treated with filtered supernatant from normal 293T cells. Cells were incubated for 2 days before being assayed for
viability with CellTiter-Glo. Statistical significance was determined using 2-tailed student’s t-test, with filtered or unfiltered experimental groups compared to the
Control groups of like type. MØ, Macrophage; RLU, Relative Luminescent Units. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
development. Finally, U937 monocytic cells showed significant
reduction in viability when treated with any of the three
supernatants, with VP40-transfected supernatants showing the
most pronounced effect (Figure 2C). These results suggest that
monocytes, in contrast to T cells, are particularly susceptible to
Ebola protein-transfected cell supernatants. When CEM, Jurkat,
and U937 cells were treated with supernatants from 293T cells
that were transfected with multiple plasmid combinations (i.e.,
VP40 + GP, VP40 + NP, GP + NP, and VP40 + GP + NP),
all three immune cell types showed significant decreases in
viability from the triple combination of VP40 + GP + NP
while only the Jurkat cells showed significant decreases from
treatment with supernatants from all transfection doublets
(data not shown). Furthermore, antibiotic alone (Hygromycin
B, Geneticin, and Zeocin) treated supernatants of 293T cells
(5 days) did not alter cell viability of immune cells (data not
shown).
As VP40 alone or VP40 + GP ± NP can form VLPs, we next
asked whether the specific size of the material in supernatants
of transfected cells contributed to the observed decrease in
viability. VLPs are distinct from other extracellular vesicles,
which can be differentiated based on a number of characteristics,
including size and surface markers. VLPs are 400 nm in size or
larger, similar to EBOV virions (Bavari et al., 2002; Noda et al.,
2002; Warfield et al., 2003), whereas extracellular vesicles (i.e.,
exosomes) are smaller than 220 nm, and typically approximately
100 nm (Fleming et al., 2014; Sampey et al., 2014). For this
reason, we passed transfected cell supernatants through a 0.22
micron filter and asked whether the same phenotype in treated
immune cells could be observed compared to those treated with
unfiltered supernatants. A side-by-side comparison of filtered
versus unfiltered supernatants showed similar effects on all cell
types (Figures 2A–C). Since filtering did not abrogate the earlier
observed effects, we concluded that it was unlikely that the
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detrimental agent within the transfected cell supernatant was
Ebola VLPs or cellular apoptotic bodies that are also larger than
400 nm (Akers et al., 2013; Schwab et al., 2015). Additionally,
these experiments indicated that the factor(s) effecting the
apoptosis was not free VP40 protein, as purified VP40 showed
little effect on U937 cell viability (Figure 1B). Collectively, these
results imply that supernatants from Ebola protein-transfected
293T cells may be capable of negatively impacting both T cells
and monocytes.
As the supernatants from cells transfected with VP40 DNA
appeared to pose greater toxicity to monocytes than to T
lymphocytes, we wished to explore further the effect of VP40
on differentiated macrophages. This was of interest since
EBOV naturally targets monocytes and especially macrophages
in vitro and in vivo during early infection (Jaax et al., 1996;
Ryabchikova et al., 1999; Geisbert et al., 2003; Falasca et al.,
2015; Messaoudi and Basler, 2015; Messaoudi et al., 2015;
Nyakatura et al., 2015; Singh et al., 2015). We differentiated
U937 monocytes into macrophages using phorbol 12-myristate
13-acetate (PMA) for 5 days, followed by treatment with purified
VP40 protein, as well as unfiltered and filtered VP40 transfection
supernatants. Differentiated cells were incubated for 5 days
and cell viability was measured using CellTiter-Glo. While
purified VP40 protein alone had no effect on differentiated U937
cell viability, both filtered and unfiltered cell-free media from
VP40-transfected cells resulted in significantly decreased cellular
viability (Figure 2D).
Next, we differentiated primary monocytes into macrophages
using PMA for 2 days and treated them with filtered supernatant
from control 293T cells, unfiltered or filtered supernatants
from VP40-transfected 293T cells, or filtered supernatants from
Ebola VP40-Transfected Resistant 293T Clone (EVTR2C) cell
supernatants. EVTR2C cells are a clone of VP40-transfected
293T cells resistant to the effects of VP40. These resistant
clones are a stable population of 100% VP40-transfected
293T cells under Hygromycin B selection. We believe that
EVTR2C cells are able to survive stably with the production
of a lower level of VP40 protein in comparison to normal
VP40-transfected 293T cells (see Materials and Methods).
Differentiated primary cells were incubated for 2 days and
cell viability was measured using CellTiter-Glo. The primary
cells were only treated for 2 days with cell supernatants as
opposed to the 5-day treatment received by the U937 cells.
Viability of the treated primary cells was noticeably decreasing
over time upon visual inspection. Strikingly, PMA-activated
primary monocyte viability was drastically reduced with the
treatment of unfiltered and filtered VP40-transfected 293T and
filtered EVTR2C cell supernatants in comparison to the control
treatment (Figure 2E). This further confirms that free, purified
VP40 protein alone exhibits no toxicity to monocytes; however,
primary monocytes that have differentiated into macrophages
are more susceptible to supernatant from VP40-producing
cells, compared to macrophages derived from monocyte cell
lines. Collectively, these data suggest that VP40 produced from
transfected cells can potentially be packaged into protected
vesicles, which in turn can exert detrimental effects on immune
recipient cells.
Exosomes from Transfected Cells
Contain Ebola VP40
We next asked whether VP40 produced in the transfected cells
was incorporated into exosomes, potentially affecting recipient
cells. The packaging of viral proteins into exosomes has been
previously shown in many other infections including HIV-1,
HTLV-1 and Rift Valley fever viruses (Meckes et al., 2013;
Fleming et al., 2014; Jaworski et al., 2014a; Sampey et al.,
2014; Ahsan et al., 2016). Incorporation into exosomes protects
the packaged proteins and nucleic acids from degradation by
extracellular enzymes and allows them to reach recipient cells.
Therefore, we concentrated vesicles from the supernatants of
transfected cells using CD63 Dynabeads and NT80/82 nanotrap
particles (NTs), which have previously been shown to effectively
capture exosomes from dilute supernatants (Jaworski et al.,
2014a,b; Sampey et al., 2016). CD63 is a tetraspanin marker
abundantly expressed on exosomes and also within virally
infected cells (Sampey et al., 2016). Additionally, we used
Dynabeads alone as a negative control, and NT229 beads which
we had observed to be a strong binder of free VP40 protein
(see data in Figure 3C). Filtered supernatants from VP40-
transfected 293T cells were treated with nanoparticle beads,
washed, resuspended in SDS Laemmli buffer, and analyzed by
Western blot for the presence of VP40 protein. VP40 was present
in the samples immunoprecipitated with CD63 and NT80/82
beads (Figure 3A, lanes 2 and 4), but was not precipitated with
Dynabeads alone, or with NT229 beads that capture purified
VP40 (Figure 3A, lanes 3 and 5). It is interesting to note that
the VP40 from exosomes exhibited a slightly higher molecular
weight, indicating selective incorporation of post-translationally
modified VP40 (i.e., phosphorylation; p-VP40) into exosomes.
We have previously shown that specific nanoparticles can
capture viral proteins, i.e., HIV-1 Tat (Narayanan et al., 2013;
Jaworski et al., 2014b). Thus, we asked whether free VP40 could
be captured with any of the newer set of 9 particles or nanotraps
described in Figure 3B. We hypothesized that there could be
free VP40, exosome-associated VP40, VLP-associated VP40, or
virally associated VP40 that could be captured using these
nanoparticles, presenting a potential diagnostic tool of EBOV
disease progression. We investigated this by treating purified
VP40 protein with nine different nanotraps (NTs 210, 212, 213,
217, 219, 222, 223, 224, and 229), some of which were previously
shown to effectively capture HIV-1 viral proteins (Narayanan
et al., 2013; Jaworski et al., 2014a,b), under two different binding
conditions: a phosphatases-buffered saline (PBS) buffer that
contained no SDS, and a second buffer that contained SDS (1:4;
Radioimmunoprecipitation assay (RIPA) and Laemmli buffer).
When using PBS alone, almost all particles, except NT213,
showed varying levels of bound VP40, with the NT229 being the
strongest binder of free VP40 (Figure 3C). However, when we
used SDS buffer, we allowed the nanotraps to bind to VLPs in
a mixture of RIPA and Laemmli buffer overnight at 4◦C. The
next day, samples were washed, isolated on a 4–20% SDS/PAGE,
and subsequently analyzed by Western blot for VP40 and GP
proteins. The bottom panels in Figure 3C show that in the
presence of SDS buffer, NT219 was the strongest binder of
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FIGURE 3 | Detection of free and exosome-associated VP40 using nanoparticles. (A) Five hundred microliters of VP40-transfected supernatant (1.75 units of
AChE) was incubated with either CD63 beads, beads alone, NT80/82 or NT229 beads. Samples were bound at 4◦C for 72 h. Pellets were isolated and washed
once with 1x PBS, followed by Western blot for VP40. Control input contained 0.9 µg of Ebola VLP (GP + VP40 + NP) in Laemmli buffer. (B) The affinity bait, core,
shell, and corresponding shell type of all nanotrap particles used. (C) One hundred nanograms of E. coli-purified VP40 were added to 20 µL of each nanoparticle
30% slurry in 100 µL PBS. Binding occurred overnight at 4◦C, beads were washed and resuspended in Laemmli buffer, and samples were run on a 4–20%
Tris-glycine SDS gel. Western blot was performed with a 1:1000 dilution of α-VP40 antibody incubated overnight, three PBS washes and incubation with 3 µL of
α-rabbit secondary antibody for 2 h, followed by development. Alternatively, 1 µg of purified Ebola VLP was added to 20 µL of each nanoparticle 30% slurry in SDS
buffer (a combination of 20 µL Laemmli buffer and 60 µL of RIPA buffer). Samples were incubated overnight at 4◦C, beads were washed once with TNE50 + 0.1%
NP40, and pellet was resuspended in Laemmli buffer. Samples were run on a 4–20% Tris-glycine SDS gel followed by Western blot with a 1:1000 dilution of α-VP40
antibody or 1:5000 dilution of α-GP antibody. Membranes were incubated overnight, treated with 3 µL of α-rabbit secondary antibody for 2 h, and developed.
(D) One hundred microliters of healthy human saliva, urine, and serum was diluted 1:3 in PBS and spiked with 2.5 µg of Ebola VLP. One hundred and fifty microliters
each of RIPA and Laemmli buffer (a total of 300 µL of 1:1 SDS buffer) was added to each sample followed by the addition of 60 µL of 30% slurry of NT219 and
rotation overnight at 4◦C. Beads were spun down the next day, washed once with TNE50 + 0.1% NP40, and resuspended in Laemmli buffer followed by
SDS/PAGE and Western blot for the presence of VP40. VLP positive controls were loaded at 0.5 and 0.1 µg.
Ebola proteins from VLP, whereas NT229 showed minimal or no
binding in this assay.
We finally asked whether VLPs spiked into bodily fluid could
be captured with NT219 beads under these strong denaturing
conditions. To that end, we spiked human saliva, urine, and
serum with VLPs and treated the samples with SDS buffer
(1:1; Laemmli to RIPA). A 30% slurry of NT219 beads was
added, samples were incubated overnight at 4◦C, washed with
TNE50 + 0.1% NP40 the next day and analyzed by Western
blot for presence of VP40 protein. As shown in Figure 3D,
NT219 beads were able to bind to VP40 in both saliva and urine
samples under these reducing conditions. The VP40 from saliva
samples contained various degraded smaller forms, whereas the
urine sample showed a single band for the protein (Figure 3D,
lanes 4 and 6). The binding efficiency was approximately 1%
under these conditions as determined by densitometry (data not
shown). Interestingly we observed no VP40 present from the
serum samples spiked with the VLP, indicating that the proteins
may have been rapidly degraded even when using SDS buffer.
Collectively, these data indicate that exosome-associated VP40
can be captured with either CD63 beads or nanoparticles from
transfected supernatants, and that the use of nanotraps in an
SDS buffer (to disrupt VLPs, and by analogy virions) may be an
alternative method in concentrating inactive Ebola proteins or
potentially nucleic acids for downstream diagnostic assays.
Ebola VP40 Is Phosphorylated by
Cyclin-Dependent Kinase 2
Our previous results in Figure 3A indicated that the VP40
incorporated into exosomes was of a slightly higher molecular
weight, suggesting a selective post-translational modification.
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FIGURE 4 | Potential activity and sites of Cdk2/Cyclin phosphorylation on Ebola VP40. (A) The amino acid sequence of Ebola VP40 with potential
phosphorylation sites (∗) and hypothesized Cdk2 phosphorylation site (red). (B) Crystal structure of EBOV VP40 monomer. Potential phosphorylation sites are
marked on two serine residues (red) and two threonine residues (blue). Previously demonstrated c-Abl1 phosphorylation site tyrosine-13 (García et al., 2012) is
indicated (green). The Ebola VP40 crystal structure modified was from Dessen et al. (2000). (C) CEM extracts were used for immunoprecipitation using α-Cdk2,
α-Cyclin E, α-Cyclin A or IgG as control. Five hundred micrograms of CEM whole cell extract was used with 10 µg of each antibody and 100 µL TNE50 + 0.1%
NP-40 for 48 h at 4◦C, followed by next day addition of Protein A/G for 2 h at 4◦C. The complexes were washed with twice with TNE50 + 0.1% NP-40 and twice
with kinase buffer, and successively used for in vitro kinase assay using purified VP40 protein (lanes 3–9) and [γ-32P] ATP. Cdk inhibitors Alsterpaullone,
Indirubin-3′-monoxime, Purvalanol A and r-Roscovitine (lanes 6–9) were used at final 1 µM concentration for 1 h at 37◦C. Densitometry analysis of kinase activity as
a percentage is shown in the bottom panel with α-Cdk2+VP40 set to 100%. (D) 293T cells were transfected with 20 µg of VP40 DNA using electroporation and
were placed under antibiotic selection (Hygromycin B). After 4 days, cells (30–40% confluent) were either untreated or blocked at G1/S phase of cell cycle with
Hydroxyurea (1 mM) for 1 day. Cells were subsequently radio-labeled with [γ-32P] ATP and a few samples were treated with r-Roscovitine (10 µM) for 4 h in complete
media. Radioactive material was subsequently removed, washed and chased with complete media for 2 h. Next, cells were removed (cell scraper), lysed with lysis
buffer, and immunoprecipitation was performed overnight with α-VP40 antibody in TNE150 + 0.1% NP-40 buffer. Protein A/G was added for 2 h and complexes
were washed twice with TNE150 + 0.1% NP-40 and once with kinase buffer. Radioactive immunoprecipitated complexes were resuspended in Laemmli buffer, run
on a 4–20% Tris-glycine SDS gel, dried, and exposed to phosphoroImager cassette. Densitometry analysis of kinase activity as determined by ImageJ software is
shown as a percentage in the bottom panel, with untreated VP40-transfected 293T cells set to 100%. (E) Five hundred micrograms of CEM whole cell extract was
immunoprecipitated with 10 µg of α-Cyclin E or normal rabbit IgG antibody in TNE50 + 0.1% NP-40, and incubated overnight at 4◦C. Fifty microliters of a 30%
slurry of Protein A/G was added next day, incubated for 2 h, washed twice with PBS and once with kinase buffer, and then resuspended in kinase buffer. Fifty
microgram of 10–12 mer peptides matching potential phosphorylation sites on EBOV VP40 were added to 15 µL of sample IP and 2 µL of a [γ-32P] ATP and kinase
buffer solution (1:3). Samples were incubated for 1 h before being dotted onto Whatman glass microfibre filters and dried for 30 min before being submerged in 1x
TE buffer with gentle agitation for 2 days. DPM2 counts were then taken with a scintillation counter (QuantaSmartTM). The peptide sequences used are illustrated in
the boxes. Underlined letters indicate the potentially phosphorylated residue. Residues that were altered from the wild type sequence are indicated (red).
It has previously been shown that VP40 is phosphorylated at
tyrosine 13 (Y13) by c-Abl1 kinase, which was necessary for
the productive replication of high titer EBOV in vitro (García
et al., 2012). Therefore, we asked whether VP40 could potentially
be phosphorylated in cells prior to packaging and release with
exosomes. The VP40 amino acid sequence contains multiple
potential sites of phosphorylation. Using our mass spectrometry
data of EBOV virions we found Ser-233, Thr-272, Thr-277,
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and Ser-278 to be potentially phosphorylated (Figures 4A,B).
The whole phosphoproteomic analysis of EBOV is ongoing and
will be published elsewhere (data not shown). Interestingly,
Ser-233 of VP40 is part of a 233SPEKI237 sequence (shown
in red; Figure 4A) which resembles the Cyclin-dependent
kinase 2 (Cdk2) phosphorylation motif (S/T)PX(K/R) (Deng
et al., 2002). To determine if Cdk2 is indeed involved in the
phosphorylation of VP40, we designed in vitro kinase assays
using cell extracts from which Cdk2 was immunoprecipitated
with α-Cdk2 antibody. In addition, antibodies against Cyclin A
and Cyclin E (α-CycA and α-CycE), which are normal partners of
Cdk2, were utilized to precipitate specific Cdk2 kinase complexes.
In vitro kinase assays were then performed using purified VP40
protein and [γ-32P] ATP. Results in Figure 4C indicate that there
is a dramatic increase in VP40 phosphorylation in the presence of
Cdk2 as compared to controls (lanes 1-3). VP40 phosphorylation
additionally increased when the kinase was precipitated with
either Cyclin E- or Cyclin A-specific antibodies (Figure 4C, lanes
4 and 5). This is consistent with the association of the Cyclins
with Cdk2 in an active kinase complex, rather than Cdk2 alone
which may represent a mixture of inactive complex (Cdk2 alone)
with active complexes (Cdk2/CycE, Cdk2/CycA) in cells.
As further confirmation of the involvement of Cdk2, we then
asked whether the phosphorylation of VP40 in vitro could be
prevented with specific Cdk inhibitors. Cdk2 inhibitors with
high selectivity such as Alsterpaullone, Indirubin-3′-monoxime,
Purvalanol A, and r-Roscovitine have previously been shown to
inhibit the replication of other viruses including HIV-1, Hepatitis
C Virus, Human Cytomegalovirus, Adenovirus, and Varicella-
Zoster Virus (Bresnahan et al., 1997; Taylor et al., 2004; Guendel
et al., 2010; Cheng et al., 2013; Munakata et al., 2014; Roy et al.,
2015). We therefore investigated if any of these inhibitors could
affect the phosphorylation of VP40 in vitro. While Alsterpaullone
and Indirubin-3′-monoxime resulted in only a moderate down-
regulation of VP40 phosphorylation (Figure 4C, lanes 6 and
7), Purvalanol A was slightly more effective (Figure 4C, lane
8), and importantly, r-Roscovitine completely inhibited the
phosphorylation of VP40 (Figure 4C, lane 9). Collectively, these
data indicate that Cdk2/Cyclin E and Cyclin A complexes
(markers of late G1 and early S phases of cell cycle) efficiently
phosphorylate VP40 in vitro, and this phosphorylation can be
prevented with specific Cdk inhibitors.
Cdk2/Cyclin E complexes are most active during the G1/S
phase of the cell cycle, however, most cell lines used in vitro
(i.e., 293T cells) are a mixed population of cells at the G1
(∼65%), S (∼20%), and G2/M (∼10%) phases. To obtain a
more uniform population of cells at G1/S, we treated cells
with Hydroxyurea (Hu), which is a reversible compound that
targets early S phase DNA synthesis (Kashanchi et al., 2000). We
transfected 293T cells with VP40 plasmid and added Hygromycin
B for plasmid selection. Cells were either untreated or blocked at
the G1/S phase with Hydroxyurea (2 mM) for 1 day. Cells were
subsequently pulsed with radio-labeled [γ-32P] ATP and treated
with r-Roscovitine for 4 h in complete media, followed by washes
and immunoprecipitations using α-VP40 antibody. The data in
Figure 4D show that VP40 is indeed phosphorylated in vivo
and its phosphorylation is inhibited by r-Roscovitine treatment.
Kinase activity as a percentage is quantified using densitometry
as illustrated in the panels beneath Figures 4C,D.
In order to confirm the specific site of phosphorylation on
VP40, we utilized five 10–12 mer specific peptides that span
various residues that are potentially modified (as shown in
Figures 4A,B). The expected target of Cdk2 phosphorylation
was Ser 233, which is part of a SPEKI sequence that resembles
Cdk2’s (S/T)PX(K/R) consensus phosphorylation site (Deng
et al., 2002). The ADLTSPEKIQAI peptide (S3) and the S233A
mutated ADLTAPEKIQAI peptide (S3M) were used in in vitro
kinase assays. The Cyclin E-precipitated Cdk2 kinase complex
was incubated with the peptide substrates and phosphorylation
was detected using Whatman glass microfibre filters. Other
potential targets were also examined using additional synthesized
peptides containing Thr-277 (GKKVTAKNGQPI, T7), Ser-278
(GKKVASKNGQPI, S8), and Thr-272 (LVHKLTGKKV, T2)
residues (Figure 4E). To distinguish between Thr-277 and
Ser-278 residues, alanine mutations were introduced: S278A
for T7 and T277A for S8. The S3 peptide containing the
putative Cdk2 phosphorylation site showed the greatest level
of phosphorylation by Cdk2/Cyclin E, which was abrogated in
the S3M mutant (Figure 4E). Peptide T7 containing the Thr-
277 site showed considerably reduced phosphorylation, and the
peptides containing Thr-272 (T2) and Ser-278 (S8) showed only
background levels of phosphorylation, similar to S3M peptide
(Figure 4E). IP experiments were conducted using CEM extracts
as we have previously shown that these cell extracts contain
active Cdk/Cyclin kinases that can easily be purified with specific
antibodies (Wang et al., 2001). Taken together, these results
suggest that VP40’s Ser-233 is the target site for phosphorylation
by Cdk2/Cyclin E.
Presence of Ebola VP40 Results in
Regulation of microRNA Machinery in
Donor and Recipient Cells
It has previously been shown that a downregulation of various
microRNA machinery components such as Dicer, Drosha,
Exportin 5 and Ago proteins have been linked to the induction
of apoptosis (Su et al., 2009; Han et al., 2013; Bian et al.,
2014; Lombard et al., 2015), while upregulation of Ago 1 has
been linked to a slowing down of the cell cycle and eventual
apoptosis (Su et al., 2009; Parisi et al., 2011: 1). Given that we
observed apoptosis in cells treated with purified VP40 protein
and supernatants from cells transfected with VP40 DNA, we
next asked whether Ebola VP40 was able to affect the cellular
miRNA machinery of transfected cells, as well as cells receiving
exosome-laden transfected cell supernatant treatments. It has
been previously shown that some viruses interfere with host
miRNA machinery as a means of evading host immune responses
important for cell signaling and regulation of apoptosis (Coley
et al., 2010; Van Duyne et al., 2012). Additionally, it has been
observed that EBOV proteins VP35, VP30, and potentially VP40
are capable of deregulating the host RNAi pathway as suppressors
of RNA silencing (Fabozzi et al., 2011). Here, 293T cells were
transfected with plasmids producing VP40 and kept under
Hygromycin B antibiotic selection. Cell pellets were harvested,
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FIGURE 5 | Inhibition of miRNA machinery in transfected donor and
recipient cells. (A) Mid-log phase 293T cells were transfected with
VP40-producing plasmids via electroporation and incubated for 24 h, followed
by treatment with Hygromycin B for plasmid selection until cells were
confluent (9 days; lane 2). Mock transfected cells were electroporated without
plasmid (lane 1). Cells were lysed with lysis buffer, whole cell extract was
resuspended in Laemmli buffer, run on a 4–20% Tris-glycine SDS gel, and
subsequently analyzed by Western blot for levels of miRNA machinery
components Dicer, Drosha, Ago 1, Exportin 5, DGCR8, and TRBP. Presence
of VP40 protein was analyzed as a control, along with Actin. NS, non-Specific
binding (B) VP40-transfected 293T cells were grown under antibiotic selection
for 14 days, followed by removal and filtering (0.22 micron) of the supernatant.
CEM cells were treated with 100, 250, or 500 µL of filtered transfection
supernatant (0.3, 0.75, and 1.5 mU AChE, respectively) and incubated for
5 days at 37◦C. Cell pellets were isolated, lysed with lysis buffer, and analyzed
by Western blot for miRNA machinery components Dicer, Drosha, Ago 1,
Exportin 5, DCGR8, and TRBP. Actin levels were also analyzed.
lysed, and analyzed by Western blot for levels of Dicer, Drosha,
Ago 1, Exportin 5, DGCR8, TRBP, VP40 and Actin. Results
in Figure 5A show a down-regulation of Dicer, Drosha, Ago
1, and DGCR8 protein levels in cells transfected with VP40
DNA in comparison to mock transfected cells. However, the
levels of Exportin 5 remained constant while TRBP levels slightly
increased.
We next examined the effects of exosomes from transfected
cells on recipient cell miRNA machinery. Exosomes were purified
from VP40-transfected cells using a 0.22 micron filter and
ultracentrifugation, followed by treatment of recipient CEM cells
with varying concentrations of exosomes (0.3, 0.75, and 1.5 mU
AChE). Recipient cells were treated for 5 days, harvested, and
analyzed by Western blot for the components of the miRNA
machinery, along with accessory proteins including TRBP and
DGCR8. Interestingly, a similar decrease was observed in the
expression of Dicer, Drosha and Ago 1 in lymphocytes treated
with the highest concentration of exosomes (Figure 5B). TRBP,
DGCR8, and Exportin 5, on the other hand, were unaffected
by VP40-associated exosomes. Together, these data suggest that
VP40 may be capable of dysregulating some specific components
of miRNA machinery components not only in infected donor
cells, but also in naïve neighboring cells receiving VP40-
containing exosomes.
Treatment of VP40-Transfected 293T
Cells with Oxytetracycline Decreases
Exosomal Release and Reduces
Recipient Cell Dysregulation
We next asked whether treatment of VP40-transfected 293T
cells with FDA-approved drugs would be able to down-regulate
the release of exosomes, and thereby potentially mitigate the
detrimental effects seen in recipient cells. We screened a panel of
FDA- and non-FDA-approved drugs to find that Esomeprazole,
Oxytetracycline, and Cambinol reduce exosomal release in HIV-
1 infected cells (unpublished data). Here, 293T cells were
transfected with VP40 DNA, placed under antibiotic selection,
and treated with increasing concentrations of 1 nM to 10 µM of
Esomeprazole, Oxytetracyline, Cambinol, or DMSO as control.
Cells were then pelleted, lysed, and analyzed by Western
blot for classic exosomal markers CD63 and Alix, as well as
Actin. Results in Figure 6A show an increase in CD63 and
Actin in cells transfected with VP40 DNA in comparison to
untransfected controls (lanes 1 and 2). In addition, a decrease
in CD63 and Actin was observed in transfected cells treated
with increasing concentrations of Oxytetracycline (Figure 6A,
lanes 6–8). Treatment of cells with increasing concentrations of
Esomeprazol, Cambinol, and DMSO resulted in no significant
differences in CD63, Alix, or Actin levels.
As Oxytetracycline showed a positive effect of potentially
down-regulating exosomal release from donor cells, we then
asked whether this same treatment on donor cells would
reduce the inhibitory effects we observed on recipient immune
cells. We placed our VP40-resistant EVTR2C cells under
varying concentrations (100 nm-10 µM) of Oxytetracycline
and incubated for 5 days. Supernatants were harvested, filtered
through a 0.22 micron filter, and then used to treat CEM,
Jurkat, or U937 recipient cells. Treatment of immune cells with
untreated, filtered 293T cell supernatant served as a negative
control. Cell viability was then assayed with CellTiter-Glo.
Results in Figures 6B,D show an expected decrease in cell
viability in the three cell types treated with EVTR2C supernatant.
Interestingly, CEM and Jurkat cells treated with 0.1, 1.0, and
10 µM Oxytetracycline showed a corresponding increase in
cell viability in a dose-dependent manner (Figures 6B,C).
U937 cells showed no significant change in cell viability
until treatment with the highest dose of Oxytetracycline
(Figure 6D). Collectively, these data indicate that an increase
in exosomal release from cells may occur in the presence of
VP40. Additionally, treatment with Oxytetracycline may cause
a reduction of exosomal release in VP40-producing cells, and
thereby diminish the inhibitory effects on neighboring recipient
immune cells.
Effect of Ebola VP40 Presence on
Exosomal Markers and ESCRT
Machinery
We have previously shown that HIV-1-infected cells have
increased levels of cytosolic unprocessed CD63, while exosomes
from HIV-1-infected cells contain increased levels of glycosylated
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FIGURE 6 | Effect of FDA approved drugs on EBOV transfected donor and recipient immune cells. (A) Varying concentrations of Cambinol and
Esomepraole (1 nM, 1 µM, 10 µM), Oxytetracycline (1 nM, 10 nM, 10 µM), and DMSO (0.00001, 0.0001, 0.001%) treatments were administered to
VP40-transfected 293T cells, followed by incubation for 3 days. Supernatant was centrifuged to remove cellular material and subsequently incubated for 72 h at 4◦C
with 20 µL of 30% slurry of NT80/82 beads. The NT pellet was washed twice with PBS and resuspended in SDS Laemmli buffer, followed by Western blot analysis
for levels of exosomal markers CD63 and Alix. Actin levels were also analyzed. Mid-log phase EVTR2C cells (containing VP40) were treated with either low (0.1 µM),
medium (1 µM), or high (10 µM) concentrations of Oxytetracycline and incubated for 5 days along with untreated 293T cells. Cell-free supernatants were harvested,
filtered, and used to treat CEM (B), Jurkat (C), and U937 (D) cells. Cells were incubated for 5 days and assayed with CellTiter-Glo for viability. Statistical significance
was determined using two-tailed student’s t-test with all groups compared to the untreated 293T cell control groups. RLU, Relative Luminescent Units. ∗p < 0.05,
∗∗∗p < 0.001.
CD63, indicating that infection results in increased CD63
production or exosome biogenesis (Narayanan et al., 2013;
Sampey et al., 2016). We likewise observed a similar increase in
the levels of CD63 in exosomes in presence of VP40 (Figure 6A,
lane 2). To further characterize this change, we used NT80/82
beads to concentrate the exosomes in supernatants from 293T
and EVTR2C cells that were simultaneously harvested and
lysed. Both exosomes and cellular extracts were analyzed by
Western blot for levels of CD63, Alix, and Actin. Results in
Figure 7A (left panel) show an increase in CD63 levels in
the presence of VP40 compared to control cells. However, the
intracellular levels of glycosylated CD63 and Alix remained
similar. In contrast, Alix and glycosylated CD63 increased
in exosomes from EVTR2C cells in comparison to controls
(Figure 7A, right panel). These data indicate that VP40 may
induce an increased total level of CD63 or an increased
production of exosomes, similar to the HIV-1-infected cell
phenotype.
As exosomal biogenesis and release is governed largely by the
ESCRT pathway, we next asked if components of the ESCRT
machinery were being affected by the presence of VP40 in
our resistant clones. EVTR2C and 293T cells were cultured to
mid-log phase, harvested, and lysed. Whole cell extracts were
analyzed by Western blot for levels of ESCRT I (TSG101), II
(EAP20, EAP45), and III (CHMP6) proteins, as well as VP40.
The data in Figure 7B show an increase in levels of TSG101,
EAP20, and EAP45 proteins in EVTR2C cells in comparison to
293T cells. Western blot also confirmed the presence of VP40
in EVTR2C cells. Finally, as we had observed a decrease in
exosomal release with Oxytetracycline treatment (Figure 6A,
lanes 6–8), we hypothesized that ESCRT components may be
dysregulated by this drug treatment. We treated EVTR2C cells
with Oxytetracycline for 5 days followed by lysis and Western
blot for ESCRT I–III protein components, as well as VP40 protein
and Actin. Data in Figure 7B (lane 3) shows that treatment
with Oxytetracycline resulted in a downregulation of ESCRT III
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FIGURE 7 | Effect of VP40 presence on exosomal markers and ESCRT machinery components. (A) 293T cells and VP40-resistant clones (EVTR2C cells)
were grown for 5 days, followed by harvesting of both cells and supernatants. Cells were lysed and analyzed by Western blot for levels of CD63, Alix, and Actin.
Supernatants were centrifuged and passed through a 0.22 micron filter, followed by incubation at 4◦C with 30% slurry of NT80/82 beads for 72 h. Beads were spun
down next day and resuspended in Laemmli buffer, followed by SDS/PAGE and Western blot analysis for levels of CD63, Alix, and Actin. (B) Whole cell extracts from
293T, EVTR2C, and EVTR2C cells treated for 5 days with 10 uM Oxytetracycline were run on a 4–20% Tris-glycine SDS gel and analyzed by Western blot for levels
of ESCRT pathway components TSG101 (ESCRT-I), EAP20 (ESCRT-II), EAP45 (ESCRT-II), and CHMP6 (ESCRT-III), as well as VP40 and Actin.
protein CHMP6. Surprisingly, levels of intracellular VP40 were
also decreased in EVTR2C cells treated with Oxytetracycline.
Together, these results indicate that exosomal markers such
as CD63 and specific ESCRT machinery components may be
upregulated in VP40-producing cells, correlating with a possible
increase in exosome production. Treatment of VP40-containing
cells with Oxytetracycline may also offer a potential tool for
decreasing the output of exosomes through inhibition of a
CHMP6-mediated pathway, or by inhibiting the production or
accumulation of VP40 within cells.
DISCUSSION
Ebola virus can cause severe hemorrhagic fever in humans and
non-human primates, resulting in up to 80–90% mortality rates
and long-term morbidity in convalescent survivors (Elshabrawy
et al., 2015; Martines et al., 2015; Singh et al., 2015). Infection
is characterized by prolific production of cytokines, unregulated
viral replication in migrating immune cells of the myeloid lineage
(dendritic cells, monocytes/macrophages), Kupffer cells in the
liver, endothelial and epithelial cells, as well as widespread
bystander lymphocyte apoptosis (Geisbert et al., 2003). In fatal
cases, the adaptive immune (T- and B-cell-mediated) response
is strongly repressed due to extensive cell death, despite a lack
of productive infection in these cells, however, survivors of
EBOV infection are able to produce the appropriate adaptive
immune responses in the absence of bystander lymphocyte
apoptosis (Geisbert et al., 2000, 2003). Our data using various
forms of VP40-containing complexes showed a dysregulation of
treated immune cells. We observed that VP40, when enclosed by
membranes and masked by GP within VLPs, showed minimal
toxicity toward both T-cells and monocytes. However, when
treated with free VP40, we observed cell death in T-cells
through the induction of Caspase 3 and cleavage of PARP-1.
We next analyzed the effects of Ebola protein-transfected cell
supernatants on T-cells and monocytes. VP40-transfected cell
supernatants, both filtered (0.22 micron) and unfiltered, resulted
in consistent amounts of cell death amongst CEM, Jurkat, and
U937 cells, as well as U937 MDMs and 3 primary MDMs,
although there was some level of cell death from NP- and GP-
transfected cell supernatants in non-differentiated recipient cells.
Furthermore, treatment with supernatants from VP40-resistant
clones (selected under Hygromycin B), resulted in cell death in
the primary MDMs, similar to treatment with VP40-transfected
cell supernatants. Interestingly, cell death occurred in monocytes
when treated with supernatants from VP40-transfected cells, but
not when treated with E. coli-purified free VP40, suggesting
that VP40 produced in eukaryotic cells may have a different
phenotype. We have previously shown that exosomes are able to
be captured and concentrated with the use of specific nanotrap
particles (NT80/82) (Narayanan et al., 2013; Jaworski et al.,
2014a,b; Sampey et al., 2016). Similarly, we were able to capture
exosomes from VP40-transfected cell supernatants with NT80/82
beads. Furthermore, Western blot of these NT samples showed
that VP40 is indeed packaged into exosomes. These data from
EBOV VP40 is similar to our recent study of exosomes from cells
infected with Rift Valley Fever Virus (enveloped ssRNA virus),
that were also found to regulate neighboring, uninfected immune
cells by destroying T-cells and monocytes (Ahsan et al., 2016).
This could potentially represent a new pathogenesis paradigm
for ssRNA viruses. Exosomes from EBOV-infected cells may
then also contain Ebola viral proteins including, but perhaps
not limited to, VP40 or other viral transcripts. Here, we show
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that VP40 incorporated into exosomes is capable of inducing
cell death in uninfected T-cell and monocyte populations, a
phenotype that is strongly reminiscent of bystander lymphocyte
apoptosis.
Currently, most Ebola research is restricted to work within a
BSL-4 biocontainment facility, greatly limiting diagnosis, sample
analysis, and in vivo studies. Therefore, we wished to determine
if it were possible to use nanotrap particles under strongly
reducing buffer conditions to safely and effectively detect viral
proteins in human samples. We were able to ascertain an effective
nanoparticle (NT219; Cibacron Blue F3G-A bait with VSA shell)
capable of binding to and concentrating Ebola VP40 protein
within VLPss spiked into human saliva or urine in the presence
of stringent SDS buffer (1:1; RIPA and Laemmli buffer). The
binding efficiency of our NT219 under these conditions was
approximately ∼1%; however, the sensitivity of this assay could
be greatly increased with the use ELISA rather than Western
blot for detection. Improvement of this method could be a
significant enhancement to our current diagnostic methods,
allowing detection of Ebola proteins in human samples to safely
be carried out in simple BSL-1 or -2 conditions or in the field with
minimal PPE and biocontainment requirements.
We observed that the VP40 found within exosomes migrated
slower on SDS/PAGE in comparison to that found within VLPs.
It has previously been shown that VP40 is phosphorylated at
tyrosine 13 (Y13) by c-Abl1 (García et al., 2012), which is required
for high levels of replication of EBOV in vitro. In this study, we
wished to see if VP40 was similarly modified prior to packaging
and release into exosomes. We found that VP40 is in fact
phosphorylated by Cdk2 in complex with either Cyclin A or
Cyclin E, although Cdk2/CycE appears to be a stronger kinase
for VP40 at the G1/early S phase. Additionally, we were able
to prevent the kinase activity of Cdk2 on VP40 with specific
inhibitor r-Roscovitine treatment. To determine the site of
phosphorylation, we designed five 10-12 mer peptides matching
VP40 residues for subsequent in vitro kinase assay. Using this
method, we found that Ebola VP40 is mostly phosphorylated by
Cdk2/CycE on Ser-233, representing a potential drug target.
Previous studies have shown that exosomes from virally
infected cells can contain functional miRNAs that are capable of
dysregulating naïve recipient cells (Pegtel et al., 2010, 2011; Barth
et al., 2011; Sampey et al., 2016). Thus, we wished to determine if
the apoptosis we observed in immune cells treated with exosomes
containing VP40 was due to the regulation of miRNA in recipient
cells. Here, we show that VP40-transfected cells have lower levels
of Dicer, Drosha, Ago 1, and DGCR8 compared to controls.
Additionally, we show for the first time that exosomes from Ebola
VP40-transfected cells are capable of downregulating the levels of
Dicer, Drosha, and Ago 1 in naïve recipient T-cells. Infection with
flaviviruses, including Dengue virus and Kunjin virus, has been
previously shown to result in the inhibition of RNAi machinery
and a downregulation of Drosha and DGCR8 (Moon et al., 2015;
Casseb et al., 2016). We also have previously shown that the
HTLV-1 protein Tax can directly modulate the RNAi pathway
through the shuttling of Drosha and Dicer to the proteasome
for degradation with no induction of apoptosis (Van Duyne
et al., 2012). Alternatively, the downregulation of various miRNA
machinery components including Dicer, Drosha, Exportin 5 and
Ago proteins have, in many cases, been linked to the induction
of apoptosis (Su et al., 2009; Han et al., 2013; Bian et al., 2014;
Lombard et al., 2015). In combination, these data support the
suggestion that EBOV VP40 within cells and incorporated into
exosomes can modulate RNAi components in both parent donor
and recipient immune cells, ultimately resulting in cell death.
This may therefore represent a novel mechanism of immune
system evasion by EBOV by inducing bystander lymphocyte
apoptosis in uninfected recipient T-cells through the delivery
of VP40-laden exosomes from infected donor cells, during the
course of infection.
In this manuscript we found that levels of the exosomal
marker CD63 increase in cells producing EBOV VP40. A side-
by-side comparison of EVTR2C cellular lysates to EVTR2C
exosome samples (obtained with NT80/82 beads) showed an
increase in CD63 levels within cells and a corresponding
increase in glycosylated CD63 and Alix in exosomal samples,
potentially correlating to an increase in exosomal biogenesis
and release. These data are supported by previous observations
of increasing CD63 levels in exosomes and from cells infected
with HIV-1 and HTLV-1 (Narayanan et al., 2013; Jaworski et al.,
2014a; Sampey et al., 2016). Recently, we have found several
FDA- and non-FDA-approved drugs that have been able to
reduce exosomal release in HIV-1-infected cells (unpublished
data). Along these lines, we wished to see if any of these
drugs (Esomeprazol, Oxytetracycline, and Cambinol) would
be effective in reversing the implied increase in exosome
biogenesis seen in cells transfected with EBOV VP40. Our initial
results indicated that CD63 levels decreased in exosomes with
increasing concentrations of Oxytetracycline treatment in a dose-
dependent manner. Additionally, a recovery of cell viability in
recipient naïve immune cells was achieved with supernatant from
Oxytetracycline treated VP40-resistant clones.
The ESCRT pathway, composed of ESCRTs -0, -I, -II, -III
complexes, and ATPase VPS4, is the main pathway responsible
for the sorting of cargo into and release of exosomes from host
cells. Early ESCRT complexes are responsible for recognizing
and sorting cargo, as well as recruiting later ESCRT complexes,
which in turn are responsible for membrane budding, scission,
and release of vesicles. VPS4 is responsible for final membrane
fusion and recycling of ESCRT complex components (Henne
et al., 2011). While the ESCRT pathway is important for exosomal
release and other cellular processes, recent studies have found
evidence that a wide assortment of enveloped viruses (i.e.,
HIV-1, SIV, HTLV-1, Lassa Fever Virus, HBV, Rabies Virus,
Japanese Encephalitis Virus, etc.) are able to hijack and utilize
ESCRT complexes in order to bud from the plasma membrane
(Votteler and Sundquist, 2013). Indeed, Ebola VP40 is capable
of recruiting TSG101 (ESCRT-I) and NEDD4 family proteins
via two different domains as a means of utilizing the ESCRT
pathway for viral budding (Harty et al., 2000; Martin-Serrano
et al., 2001; Timmins et al., 2001, 2003; Licata et al., 2003; Yasuda
et al., 2003). Therefore, to further characterize the mechanism
of action of exosomal release in the presence of EBOV VP40,
we analyzed VP40-resistant clones either alone or treated with
Oxytetracycline for levels of ESCRT complex proteins. We found
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that the levels of TSG101 (ESCRT-I), as well as EAP20 and EAP45
(ESCRT-II) increased in the presence of VP40. This resembles a
pattern seen in HIV-1 infection, where Nef and Gag regulate the
release of exosomes through the manipulation and recruitment
of ESCRT-I and ESCRT-III complexes (Lenassi et al., 2010). In
addition, we show that with Oxytetracycline treatment the levels
of CHMP6 (ESCRT-III) decrease in the VP40-resistant clones,
which may represent a method by which exosomal biogenesis
and release may be inhibited. Surprisingly, we also observed
that the levels of VP40 inside EVTR2C cells decreased in the
presence of Oxytetracycline. Future experiments will further
characterize this phenomenon and determine the mechanism
by which Oxytetracycline or other Tetracycline derivatives may
affect intracellular or extracellular levels of VP40 in EVTR2C
cells. Collectively, these data may present a potential novel
therapeutic option for the treatment of EBOV infection with
an FDA-approved antibiotic to prevent progressing pathogenesis
and bystander apoptosis.
While Ebola has not been considered as a virus exhibiting
latency, the proposed reservoir of Ebola (i.e., bats) can possess
one or more functionally maintained copies of filovirus-like
genes within their genomes, indicating that despite the virus’
cytoplasmic replication and lack of viral reverse transcriptase,
successful integration into the mammalian host genome is
possible (Belyi et al., 2010; Taylor et al., 2010, 2011). Specifically,
the nucleocapsid (NP), matrix (VP40), and potentially GP genes
from Ebola have been discovered to be integrated into the bat
genome (Belyi et al., 2010). Therefore, cases of viral recurrence
and persistence in survivors of infection could potentially be
explained by a true viral latency from an integrated form of EBOV
(potentially through cellular telomerase enzyme which contains
RT activity). Numerous studies have demonstrated that cellular
proteins, mRNAs and miRNAs from many different cell types
can be sorted and released in exosomes to affect neighboring
cells (Lotvall and Valadi, 2007; Skog et al., 2008). Furthermore,
previous studies have described the packaging of viral proteins
and miRNAs into exosomes, as well as the transfer of these
exosomes into uninfected, neighboring cells to alter cellular
activity (Pegtel et al., 2010, 2011; Barth et al., 2011; Pegtel et al.,
2011; Narayanan et al., 2013; Ahsan et al., 2016; Sampey et al.,
2016). It therefore stands to reason that if a form of EBOV may
potentially be integrated into the human host genome, that any
products of this proviral form might be passed to other healthy
cells through exosomes, and thereby induce some recurrence of
illness. Along these lines, positive PCR results in cases of EBOV
disease recurrence may not be from entire, replicative virus, but
possibly from pieces of the EBOV genome that have integrated
into the host genome.
In this study, we sought to discover if Ebola structural proteins
(NP, GP, and VP40) can be packaged into exosomes to affect other
neighboring cells. It has been demonstrated previously that direct
infection of cells with EBOV does not result in the apoptosis
of the infected cells. Rather, it has been shown that infected
cells take part in a non-apoptotic form of cell death: necrosis
(Olejnik et al., 2013; Falasca et al., 2015). In contrast, the cell death
by apoptosis of uninfected, bystander lymphocytes has been
observed under many different circumstances (Baize et al., 1999,
2000, 2002; Geisbert et al., 2000, 2003; Bradfute et al., 2007, 2010;
FIGURE 8 | Model for Ebola VP40 role in pathogenesis. VP40 within the Ebola-infected host cell will interact with the ESCRT pathway and be packaged into
exosomes. Exosomes containing EBOV VP40 exit the cell and downregulate miRNA machinery (i.e., Dicer, Drosha, Ago 1) in recipient cells, including T-cells and
monocytes/macrophages (MØ). Subsequent bystander lymphocyte apoptosis is increased, potentially resulting in immune system repression and increased viral
replication in various compartments of the host.
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Gupta et al., 2007; Wauquier et al., 2010), although the molecular
mechanism for the induction of apoptosis has not been defined.
Here, we have shown for the first time that Ebola VP40 is able to
be packaged into host cell exosomes, and that these exosomes can
negatively impact the viability of recipient naïve immune cells,
potentially causing bystander lymphocyte apoptosis in T-cell
populations (Figure 8). We therefore speculate that in an in vivo
infection there is a significant contribution of EBOV protein-
containing exosomes to pathogenesis and poor prognosis. As
such, we have provided a possible method of prevention of
this exosomal packaging and release with the use of FDA-
approved antibiotics such as Oxytetracycline, which could allow
for the development of an effective adaptive immune response in
infected patients and providing a better chance of survival.
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